In the design of anti-cancer drugs, optimizing lipophilicity is crucial. Drugs with balanced lipophilicity demonstrate better bioavailability and target specificity. Researchers strive to create compounds that are lipophilic enough to penetrate cells but not so lipophilic that they accumulate in fatty tissues, which can lead to adverse effects.
